CT-1498: A Global Phase 1B Study of JNJ-90014496, A CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Krish Patel, Matthew Ku(St Vincent's Hospital Melbourne), Melissa Beelen(Janssen (United States)), Maeve O’Reilly(Royal London Hospital), Nosha Farhadfar(University of Florida Health), Aravind Ramakrishnan(Fred Hutch Cancer Center), Luke Mountjoy(Colorado Blood Cancer Institute), Constantine S. Tam(The Alfred Hospital), Yasmina Serroukh(Erasmus MC), Kathleen Dorritie(University of Pittsburgh), Jianmei Wu(Johnson & Johnson (United States)), Mahipal Suraneni(Johnson & Johnson (United States)), Ahmed Abdulgawad(The Christie NHS Foundation Trust), Leen Slaets(European Organisation for Research and Treatment of Cancer), Arnob Banerjee(Johnson & Johnson (United States)), Jacqueline Bussolari(Johnson & Johnson (United States)), Joanna Rhodes(Roswell Park Comprehensive Cancer Center), Allison Barraclough(Fiona Stanley Hospital), Martin Hutchings(University of Copenhagen), Alfredo Perales‐Puchalt(The Wistar Institute), Youngil Koh(Seoul National University), John Kuruvilla(Princess Margaret Cancer Centre), Margot Jak, Umar Farooq(Wake Forest University), Daniel Morillo(Sheba Medical Center), Won Seog Kim(Samsung Medical Center), John D. Baird(University of Guelph), Jacob Haaber Christensen(Odense University Hospital), Julie S. Larsen(Janssen (United States)), Matthew Schwede(Stanford University), L Mayer(Hospital Clínic de Barcelona), Paul Shaughnessy(CHRISTUS Transplant Institute)

Clinical Lymphoma Myeloma & Leukemia

August 28, 2025

Cited by 1

|The Lancet|2014|4.7k

|New England Journal of Medicine|2016|2k

|The Lancet|2021|1.7k

|New England Journal of Medicine|2014|1.6k

|New England Journal of Medicine|2015|1.6k

Related Papers